Innovation in Probiotics and CDMO SolutionsAt Zinereo Pharma, we are leaders in the development and manufacturing of pharmaceutical-grade probiotics designed to improve health and well-being in key areas such as women’s health (fertility, urology, and gynecology); respiratory health (covering both pediatric and adult populations); gastroenterology,... Our commitment to science and innovation positions us as a benchmark in the probiotics sector.
With over 80 years of experience in the pharmaceutical industry, we combine our expertise in biotechnology and microbiota to offer innovative solutions that make a difference in both human and animal health.
We are proud to offer a portfolio of more than 15 innovative products available in over 10 countries, while continuing to develop new solutions for future health challenges. In addition to our probiotic portfolio, we provide customized CDMO services, from development to manufacturing, helping our clients bring their products to market with quality and efficiency.
| Sales markets | Africa; Asia; Central/South America; Middle East |
|---|---|
| Primary business activity | Contract Manufacturer |
| Affiliated categories: | Other Microorganisms & Probiotics |Other Prebiotics |Biotic products More |

19 Jun 2025
Our Business Unit Director, Ana Nunes, has been featured in Microbiome Post in an interesting interview. In this article, she dives into the origins of Zinereo Pharma, our unique positioning at the intersection of pharmaceutical heritage and biotech innovation, and how we are setting new standards in microbiome-based healthcare, especially in reproductive health.
Read more9 Mar 2025
Ligilactobacillus salivarius PS11610 mejora el éxito de la fertilización mediante FIV: un análisis retrospectivo preliminar
Read more9 Mar 2025
Ligilactobacillus salivarius PS11610 ejerce un efecto sobre el perfil microbiano e inmunológico de parejas con infertilidad desconocida.
Read more